PANAPHIX
"Non-narcotic" Cancer pain treatment & No side-effects & tolerances

“Panaphix” is a non-narcotic cancer pain reliever with no side effects. In phase 1 clinical trial of Kominox for metastatic or locally progressed hormone unacceptable prostate cancer, the effect of arsenic to control cancer pain or/and inflammatory pain was shown. After then, R&D for pain-relieving agent was started. At first, the pain-reliveing effect was evaluated in animal models of inflammatory pain, cancer metastasis-induced bone pain and neuropathic pain.

Rationale for PAX-1-001 Clinical Development
  • KOMIPHARM’s new drug PAX-1 (NaAsO2) is undergoing development as an anticancer drug. In clinical trials, a dosage of 15mg/day is taken orally to treat cancer. KOMIPHARM is also developing a dosage of 10mg/day for the relief of cancer-related pain, as an alternative to opioid drugs
  • Clinical studies in South Korea and Germany have demonstrated PAX-1’s efficacy in cancer pain relief. Currently the WHO only recommends non-opioid pain killers in Stage 1 of pain management. However, PAX-1 has the potential to replace opioids in Stage 3 as an effective and safe alternative
  • PAX-1 reduces cancer pain by inhibiting the production and release of pro-inflammatory cytokines including interleukin 1β (1L, 1β) and interleukin 18 (1L-I8)
Reducing Opioid analgesic use by developing a safer alternative (PJ Code: PAX-1-001)

RATIONALE

  • 80% of terminally ill cancer patients suffer from pain, with 60% suffering severe pain
  • WHO recommends the following stages of using analgesia
  • · Stage 1: The use of non-opioid pain killers
  • · Stage 2: The use of opioid pain killers
  • · Stage 3: The use of high-dosage, high-potency opioid pain killers
  • Opioid pain killer use is associated with many adverse effects including addiction, dependency, drowsiness, nausea, constipation and psychiatric effects. They often need to be given with other medications such as antidepressants, antipsychotics, anticonvulsants, anxiolytics and laxatives to manage the side effects
  • The development of an effective non-opioid pain killer to treat moderate to severe pain in cancer patients with minimal side effects is vital to improve patient quality of life and outcomes